Vienna Austria, September 25, 2015 – Hookipa Biotech AG, today announced that the company's
Chief Executive Officer, Dr. Katherine Cohen, will provide an overview of the company’s technologies
and programs at the Biotech in Europe Forum 2015 (Basel, Switzerland, September 29-30;
presentation on Tuesday, September 29 at 12:30 p.m. CET).
About Hookipa Biotech
Hookipa Biotech AG is developing a new class of innovative immunotherapeutics and vaccines based
on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel immunotherapy
platform using a replication-defective viral vector for the prevention and treatment of cancer and
infectious diseases. The platform is one of the most promising new technologies for next generation
immunotherapy & vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune
responses. Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave®
based immunotherapy can be applied repeatedly to boost the immune system. The Company is
developing a lead product candidate HB101, a vaccine for immunization against cytomegalovirus
(CMV) and also in the process of industrializing the Vaxwave® technology and building a robust
product pipeline in the area of immuno-oncology and infectious diseases.
Hookipa has raised a total of € 27 million in equity finance from internationally renowned venture
capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim
Venture Fund, Takeda Ventures and BioMedPartners.
Dr. Katherine Cohen
Chief Executive Officer
Hookipa Biotech AG
1030 Vienna, Austria